{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:29:29Z","timestamp":1783211369516,"version":"3.54.6"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":436,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>HeartMate 3 (HM3) left ventricular assist devices (LVADs) offer improved haemocompatibility-related outcomes for end-stage heart failure patients, facilitating the exploration of alternative anticoagulation therapies beyond warfarin. This study presents a long-term evaluation of thrombotic and bleeding outcomes in HM3 LVAD patients transitioned from warfarin to apixaban.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively identified HM3 LVAD patients at our single centre who transitioned from warfarin to apixaban. Baseline characteristics were described at discharge from implant hospitalization and at the last follow-up on each anticoagulation regimen. We reported survival, thrombo-embolic events (including LVAD pump thrombosis, stroke, arterial thrombo-embolic events and pump exchange) and bleeding events on both warfarin and apixaban.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight patients were identified between May 2018 and June 2022 who transitioned from warfarin to apixaban 5 mg twice daily. Patients were followed for a mean of 1233 days after LVAD implantation and 789 days after transition to apixaban. All patients were transitioned due to difficulty maintaining a therapeutic international normalized ratio (INR), including five patients who experienced bleeding complications on warfarin. No patients encountered LVAD pump thrombosis, stroke events, arterial thrombo-embolic event, pump exchange or death. While on warfarin, five patients had eight bleeding events: one major [requiring 2 units of packed red blood cells (pRBCs)] and seven minors (five gastrointestinal bleeds, one episode of haematuria and one episode of haemoptysis). After switching to apixaban, one patient with angioectasia had a major gastrointestinal bleed requiring two pRBCs and endoscopic clipping.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Apixaban demonstrated safe and favourable long-term outcomes in a cohort of HM3 LVAD patients over a mean follow-up of more than 2 years. To our knowledge, our report provides the longest follow-up duration for this patient population to date. Larger prospective studies are needed before this can be adopted as the standard of care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15182","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T02:39:01Z","timestamp":1733798341000},"page":"1714-1718","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-Term Outcomes of Apixaban as Main Anticoagulant in Patients with HeartMate 3 Left Ventricular Assist Devices"],"prefix":"10.1093","volume":"12","author":[{"given":"Jennifer","family":"Jdaidani","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Staten Island University Hospital, Northwell Health , New Hyde Park, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Shadi","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Staten Island University Hospital, Northwell Health , New Hyde Park, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nnedi","family":"Asogwa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Staten Island University Hospital, Northwell Health , New Hyde Park, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Winik","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, North Shore University Hospital, Northwell Health , New Hyde Park, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Rossi","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, North Shore University Hospital, Northwell Health , New Hyde Park, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Saikus","sequence":"additional","affiliation":[{"name":"Cardiovascular and Thoracic Surgery, North Shore University Hospital, Northwell Health , New Hyde Park, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria D.","family":"Avila","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, North Shore University Hospital, Northwell Health , New Hyde Park, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7536-3090","authenticated-orcid":false,"given":"Geurys R.","family":"Rojas-Marte","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Staten Island University Hospital, Northwell Health , New Hyde Park, New York ,","place":["USA"]},{"name":"Cardiovascular Institute, North Shore University Hospital, Northwell Health , New Hyde Park, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"2026021804233633300_ehf215182-bib-0001","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/jama.2022.16197","article-title":"Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial","volume":"328","author":"Mehra","year":"2022","journal-title":"JAMA"},{"key":"2026021804233633300_ehf215182-bib-0002","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5058","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"28","author":"L\u00f3pez-L\u00f3pez","year":"2017","journal-title":"BMJ"},{"key":"2026021804233633300_ehf215182-bib-0003","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/MAT.0000000000001650","article-title":"Apixaban: alternative anticoagulation for HeartMate 3 ventricular assist device","volume":"68","author":"Whitehouse","year":"2022","journal-title":"ASAIO J"},{"key":"2026021804233633300_ehf215182-bib-0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2021.01.1091","article-title":"Safety of direct oral anticoagulants in left ventricular assist device patients","volume":"40","author":"Kos","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"2026021804233633300_ehf215182-bib-0005","doi-asserted-by":"publisher","DOI":"10.1161\/circ.148.suppl_1.13717","article-title":"Abstract 13717: apixaban vs warfarin for LVAD anticoagulation","volume":"148","author":"Soares","year":"2023","journal-title":"Circulation"},{"key":"2026021804233633300_ehf215182-bib-0006","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.jchf.2024.04.013","article-title":"Evaluation of the hemocompatibility of the direct oral anticoagulant apixaban in left ventricular assist devices: the DOAC LVAD study","volume":"12","author":"Shah","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026021804233633300_ehf215182-bib-0007","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1161\/CIRCULATIONAHA.124.069726","article-title":"A prospective randomized trial of direct oral anticoagulant therapy with a fully magnetically levitated LVAD: the DOT-HM3 study","volume":"150","author":"Netuka","year":"2024","journal-title":"Circulation"},{"key":"2026021804233633300_ehf215182-bib-0008","volume-title":"Was DOAC to blame for patient's LVAD pump thrombosis? [Internet]","year":"2022"},{"key":"2026021804233633300_ehf215182-bib-0009","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/ajhp\/zxac028","article-title":"Apixaban as an alternative to warfarin for patients with a left ventricular assist device","volume":"79","author":"Horn","year":"2022","journal-title":"Am J Health-Syst Pharm"},{"key":"2026021804233633300_ehf215182-bib-0010","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1097\/MAT.0000000000001889","article-title":"Apixaban anticoagulation in children and young adults supported with the HeartMate 3 ventricular assist device","volume":"69","author":"Kobayashi","year":"2023","journal-title":"ASAIO J"},{"key":"2026021804233633300_ehf215182-bib-0011","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1001\/jama.2023.23204","article-title":"Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure: the ARIES-HM3 randomized clinical trial","volume":"330","author":"Mehra","year":"2023","journal-title":"JAMA"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/1714\/66955887\/eschf_12_3_1714.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/1714\/66955887\/eschf_12_3_1714.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:23:44Z","timestamp":1771406624000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/3\/1714\/8488302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":11,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,12,9]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15182","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2024,12,9]]},"assertion":[{"value":"2024-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}